Attached files
| file | filename |
|---|---|
| EX-32.1 - EXHIBIT 32.1 - Synthetic Biologics, Inc. | v459847_ex32-1.htm |
| 10-K - FORM 10-K - Synthetic Biologics, Inc. | v459847_10k.htm |
| EX-32.2 - EXHIBIT 32.2 - Synthetic Biologics, Inc. | v459847_ex32-2.htm |
| EX-31.2 - EXHIBIT 31.2 - Synthetic Biologics, Inc. | v459847_ex31-2.htm |
| EX-31.1 - EXHIBIT 31.1 - Synthetic Biologics, Inc. | v459847_ex31-1.htm |
| EX-21 - EXHIBIT 21 - Synthetic Biologics, Inc. | v459847_ex21.htm |
| EX-10.58 - EXHIBIT 10.58 - Synthetic Biologics, Inc. | v459847_ex10-58.htm |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
Synthetic Biologics, Inc.
Rockville, MD
We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (Nos. 333-180562, 333-189794, 333-188219, 333-156973, 333-206267, 333-207327, 333-206266, 333-203323 and 333-203322) and Form S-8 (Nos. 333-192355, 333-170858, 333-148764,333-206268 and 333-213388) of our reports dated March 2, 2017, relating to the consolidated financial statements and the effectiveness of Synthetic Biologics, Inc.’s Internal Control over Financial Reporting, which appear in this Form 10-K. Our report on the consolidated financial statements contains an explanatory paragraph regarding the Company's ability to continue as a going concern.
/s/ BDO USA, LLP
BDO USA, LLP
Troy, MI
March 2, 2017